The objective of present study was to formulate directly compressible Oro improved solubility by using solid dispersion technique. Nitazoxanide treatment of giardiasis and crystopordiasis. Solid dispersion of nitazoxanide was prepared by Kneading method and physical mixture using polymer as a carrier and using three different drug:carrier ratios;1:0.5, 1:1 and 1:3.Saturation solubility of drug was determined in physical mixture and solid dispersion. Formulation batches of solid dispersion were characterized by drug content, FTIR Spectroscopy, DSC and nitazoxanideis converted into amorphous state during formulat nitazoxanide were designed using optimized solid dispersion and crospovidone dispersible tablet shows disintegration time 54seconds and dispersible tablet (-) shows disintegration time of60minutes. Thus solid dispersion based oro patient compliance and convenience.

Novel isoxazoline derivatives were synthesized by condensation of substituted acetophenones with aldehyde in presence of alcoholic NaOH to get intermediate chalcones, which were further treated with hydroxylamine hydrochloride in presence of sodium hydroxide to get isoxazoline derivatives. The latter were refluxed separately with isonicotinic acid hydrazide and sulphanilamide in presence of formaldehyde for 6-10 h to afford corresponding Mannich bases. The structures of synthesized compounds were established on the basis of melting point, TLC, IR, 1H NMR and HRMS. Antimycobacterial activity of compounds (3a-j) were assessed against M. tuberculosis (vaccine strain, H37 Rv strain) ATCC27294 using microplate Alamar Blue assay (MABA). Further the derivatives were evaluated for the antibacterial activity against Gram positive bacteria S. aureus (ATCC 9144), S. epidemidis (ATCC12228) and Gram negative bacteria E. coli (ATCC 25922), Klebsiella (ATCC 4352), while antifungal activity against A. flavus (ATCC 9643) and A. niger (ATCC 16404) by using agar well diffusion method using ciprofloxacin and fluconazole as standards, respectively. The results of antimicrobial studies showed that some of the derivatives posses mild to moderate biological activity as compared to standard.

No abstract

A simple, precise bioanalytical UPLC Tandem Mass Spectroscopy gradient elution method was developed and validated for simultaneous estimation of Olmesartan Medoximil (OLM) and Metoprolol Succinate (MET) in human plasma. The quantitation carried out using Shimadzu Shimpack-C18 GIST AQ (50 mm X 2.1 mm, 1.9 µm) column and the mobile phase A comprises of 0.1% formic acid and mobile phase B as acetonitrile used for gradient elution. Analysis completed within run time of 4 min at the mobile phase flow rate of 0.3mL/min. The retention time of metoprolol succinate and olmesartan medoximil were 1.029 min and 2.514min, respectively. Analytes were extracted using acetonitrile as extracting solvent. The method validated in terms of linearity, accuracy, precision, lower limit of quantitation, method sensitivity and various solution stability parameters. Linearity of olmesartan medoximil and metoprolol succinate was in the range of 5-1500ng/mL. All the method validation parameters were determined as per ICH, EMA and FDA guidelines and falls under the stated acceptance criteria. The presented work provides a validated bioanalytical method for simultaneous determination of olmesartan medoximil and metoprolol succinate in human plasma. The method is accurate, simple, precise, fast and suitable for its application for bioequivalence and pharmacokinetic studies.

Review: 23 refs.